Sobi®, a leading figure in the field of biopharmaceuticals, plans to present new data at the 17th European Association of Haemophilia and Allied Disorders (EAHAD) conference in Frankfurt from February 6-9, 2024. The studies being presented demonstrate Sobi’s ongoing commitment to advancing treatment options for individuals with haemophilia.
In the words of Lydia Abad-Franch, Head of R&D and Chief Medical Officer at Sobi, “We are proud to showcase new data at EAHAD 2024, including several new data sets that add to the substantial evidence supporting the use of efanesoctocog alfa in children and highlighting improvements in patient-reported outcomes. Our hope is that these advancements will open new possibilities for people with haemophilia.” Abad-Franch added, “We will also present further data reinforcing the comprehensive evidence supporting the safety and effectiveness of Elocta® and Alprolix®. Sobi’s involvement at EAHAD underscores our continued dedication to advancing knowledge and raising standards of care.”
Key presentations to be made by Sobi at EAHAD 2024 include Is “Efanesoctocog Alfa – Joint Sobi/Sanofi Effective protection with once-weekly efanesoctocog alfa in children,” as well as “Real-world effectiveness and safety of a recombinant Factor VIII Fc in patients with haemophilia A by disease severity: Pooled analysis (A-SURE/PREVENT).”
All presentations can be accessed through the official EAHAD 2024 website.
Efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] stands as a new class and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels for a significant amount of time, improving bleed protection once weekly for individuals living with haemophilia A. This treatment is approved and marketed as ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the United States, Japan and Taiwan, and has also earned Orphan Drug designation by the European Commission in June 2019; the European Medicines Agency accepted the Marketing Authorisation Application (MAA) for efanesoctocog alfa in May 2023.
Elocta®/Eloctate® (efmoroctocog alfa) is a recombinant clotting factor therapy developed for haemophilia A using Fc fusion technology to prolong circulation in the body. Similarly, Alprolix® (eftrenonacog alfa) is a recombinant clotting factor therapy designed for haemophilia B using Fc fusion technology to extend circulation in the body. Both have been developed and are marketed by Sobi across multiple countries.
Sobi®, a specialized international biopharmaceutical company, is dedicated to delivering innovative medicines in the areas of hematology, immunology, and specialty care. Employees are located worldwide, and in 2022, revenue amounted to SEK 18.8 trillion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi can be found at sobi.com.
For details on how to contact the Sobi Investor Relations Team, please click here. And for Sobi Media contacts, click here.
Source link
